Results of clinical testing on Neuvenge, a tailor-made breast cancer vaccine by Dendreon Corporation, were released this past week, in the Journal of Clinical Oncology, and indicated that the new treatment is safe. The vaccine is made using immune cells of patients with her2/neu-positive breast cancer, a type of breast cancer that accounts for 20-30% of cases.
The treatment was tested on 18 women in the Phase I Clinical Safety trial. However, the efficacy of the vaccine did not appear especially promising according to results published in an article by Reuters. It was tested on women with advanced cancer that had progressed in spite of prior treatments. The potential of the new vaccine to effectively treat a larger pool of women, or those with less advanced disease, remains to be shown in the Phase II study.